Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Gene-editing nano-therapeutics for Cancer.

Heliyon·2024
Same author

rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering.

Antibody therapeutics·2024
Same author

Optimization and Validation of a Harmonized Protocol for Generating Therapeutic-Grade Dendritic Cells in a Randomized Phase II Clinical Trial, Using Two Varied Antigenic Sources.

Vaccines·2024
Same author

MicroRNA Expression Profile in Early-Stage Breast Cancers.

MicroRNA (Shariqah, United Arab Emirates)·2023
Same author

Development and Evaluation of p16 based Double Antibody Sandwich ELISA for Detection of Cervical Precancer and Cancer.

Asian Pacific journal of cancer prevention : APJCP·2023
Same author

Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.

Annals of clinical biochemistry·2023

Related Experiment Video

Updated: May 12, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Potential molecular targets for Ewing's sarcoma therapy.

Babu Jully1, Thangarajan Rajkumar

  • 1Department of Molecular Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India.

Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology
|April 13, 2013
PubMed
Summary

New therapeutic targets are crucial for treating Ewing sarcoma (ES), a rare childhood cancer. Research highlights potential molecular targets offering hope for improved treatments and reduced side effects.

Keywords:
Dose-limiting toxicityEwing's sarcomamolecular targets

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: May 12, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

  • Pediatric Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ewing sarcoma (ES) is a rare, aggressive cancer primarily affecting children and young adults.
  • Current treatments combining chemotherapy, surgery, and radiation yield limited success rates, especially for metastatic disease.
  • Long-term survivors face significant therapy-related side effects, including infertility and secondary cancers.

Purpose of the Study:

  • To review potential molecular targets for innovative Ewing sarcoma therapies.
  • To discuss the need for novel approaches to improve treatment efficacy and minimize toxicity.
  • To provide an overview of promising therapeutic strategies for Ewing sarcoma.

Main Methods:

  • Literature review of current and emerging Ewing sarcoma treatment strategies.
  • Analysis of molecular targets investigated in preclinical and early-phase clinical trials.
  • Synthesis of data on the efficacy and toxicity of novel pharmaceutical agents.

Main Results:

  • Existing treatments for Ewing sarcoma have suboptimal cure rates, particularly for metastatic cases.
  • Many novel agents tested in recurrent ES have shown minimal response rates.
  • Effective new drugs often present dose-limiting toxicities, necessitating safer alternatives.

Conclusions:

  • Identification of novel molecular targets is essential for advancing Ewing sarcoma treatment.
  • Targeted therapies hold promise for improving outcomes and reducing treatment-related harm.
  • Further research into these molecular targets is critical for clinical application in Ewing sarcoma.